The core activity of Quercis Pharma AG is the development of pharmaceuticals, particularly the research and development of medications for the prevention of thrombosis and other diseases, such as cancer and neurological disorders. The company focuses on the development of Isoquercetin-based medications, such as Kinisoquin, and conducts clinical trials to test their efficacy and safety.
AI-generated
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of investigational therapies based on Isoquercetin, including Kinisoquin™ and combinations with Zafirlukast, for multiple indications in oncology and beyond.
Clinical development in thrombosis and cancer
Clinical programs for the prevention and treatment of cancer-associated thrombosis, venous thromboembolism and hypercoagulability, including Phase 2 and Phase 3 studies.
Clinical development in sickle cell disease
Research and development program for sickle cell disease with Phase 2 and Phase 3 studies to reduce clotting and crises.
Clinical development in ALS, COPD and viral diseases
Further clinical programs in ALS, COPD and viral diseases focusing on inflammation, thrombosis, biomarkers and anti-thrombotic potential.
Expanded Access Program
Access to investigational medicines outside clinical trials for eligible patients with severe or life-threatening disease, assessed case by case by the treating physician.
Knowledge
No knowledge articles yet
Once Quercis Pharma AG has claimed this profile, we'll publish editorial articles and case studies here together.